CEO Rohan buys 5,000 ETNB shares at $7.89; stock down 41.9% from 52-week high, company posts -$149.1M net loss.
CEO Palekar Rohan purchased 5,000 shares at $7.89 on 2024-12-06, increasing his holdings to 471.2K shares. The purchase occurs as 89bio trades significantly below its 52-week high at $13.77, currently at $8.00, and follows a steep 23.4% decline over the prior 30 days. This marks Rohan's second open-market buy transaction in his track record, preceded by two sales with a 50.00% 90-day well-timed rate at other tickers. At ETNB specifically, Rohan has conducted three prior trades: a buy on 2024-11-22 (outcome not yet measurable), a sell on 2024-04-01 (90d return -26.6%), and a sell on 2024-12-29 (90d return +3.9%), with only 1 of 2 prior trades well-timed at the 90-day mark. The company reported a full-year net loss of -$149.1M with a market cap of $849.0M, indicating significant operational challenges. The close timing of the November and December buys warrants investor attention to whether deterioration has stabilized or if additional insider activity follows.
ETNB CEO Rohan bought 10,000 shares at $8.35 on 2024-11-22; stock down -34.9% from 52-week high amid unprofitability
ETNB CEO Rohan purchased 10,000 shares at $8.35 on 2024-11-22, increasing his holdings from 456,236 to 466,236 shares. The transaction follows a sharp drawdown: the stock trades -34.9% from its 52-week high of $13.77 and has declined -2.0% over the past 90 days despite a +13.8% bounce in the past month. The company posted a net income of $-149,073,000.00 for its most recent full fiscal year, indicating continued unprofitability. While the recent 30-day price recovery is notable, Rohan's own historical sales at this ticker show mixed timing: his two prior ETNB sales yielded 90-day returns of -26.6% and +3.9%, placing him 1 of 2 well-timed at the 90-day mark. The open-market purchase at a depressed price level merits observation for whether it represents conviction in a recovery from an unprofitable operating state.
